Table 1 Patient demographics.

From: Progression of index metastases in oligometastatic hormone-sensitive prostate cancer: implications for metastases directed therapy?

 

n (%)

Median PSA (ng/ml, IQR)

32.8 (15.4–79.6)

ISUP group

1

1 (1.5)

2

4 (5)

3

8 (10)

4

27 (34)

5

38 (48)

Not known

1 (1.5)

cT Stage

T2

11 (14)

T3a

15 (19)

T3b

37 (47)

T4a

13 (16)

Unknown

3 (4)

cN Stage

N0

53 (67)

N1

26 (33)

cM Stage

M1a

22 (28)

M1b

57 (72)

Number of bony metastases

1

38 (67)

2

9 (16)

3

7 (12)

4

2 (3)

5

1 (2)

Hormonal Therapy

ADT

20 (25.3)

ADT + ARPI

47 (59.5)

ADT + Docetaxel

11 (13.9)

ADT + ARPI + Docetaxel

1 (1.3)

Back to article page